This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Stocks Under $10 Set to Soar

Stocks in this article: PSTI CRTX VRNG PACB ZLCS


One final under-$10 name in the biotechnology and drugs complex that looks ready for a large move higher is Zalicus (ZLCS), which discovers and develops treatments for patients suffering from pain and immuno-inflammatory diseases. This stock is off to a slow start in 2012, with shares off by over 15% so far.

This company has a major catalyst on the horizon, since it will meet with the FDA on Sept. 30 to review its phase II topline data for its rheumatoid arthritis drug Synavive. This major event could lead to a large run-up in this stock as trades pile in to get in well before any bullish FDA news.

If you take a look at the chart for Zalicus, you'll see that this stock recently made a monster run from 71 cents per share to a high of $1.62 a share. During that move, shares of Zalicus were uptrending perfectly, with the stock making higher lows and higher highs, which is bullish technical price action. Also, during that run monster upside volume flowed into the stock early on in the move. After hitting that high of $1.62, shares of ZLCS have completely reversed its uptrend and plunged down to its recent low of 95 cents per share. That said, it now looks like ZLCS is gearing up to make another monster run higher if it can clear some key moving averages.

Traders should now look for long-biased trades in ZLCS if this stock can manage to hold its recent lows near 95 to 88 cents per share, and then take out both its 200-day moving average at $1.09 and its 50-day at $1.10 a share with high volume. Look for a sustained move or close above those key moving averages with volume that's near or above its three-month average action of 2.3 million shares. If we get that action, then ZLCS should easily re-test and possibly blow right through that recent high of $1.62 a share.

One could look to buy this stock off any weakness and simply target your stops just under 88 cents per share. It's possible that ZLCS could fall down to 80 or 70 cents per share if another biotech player, Horizon Pharma (HZNP), were to receive a bad ruling from the FDA on its rheumatoid arthritis drug today. I don't think that's going to happen for HZNP though, but it's good to be prepared. You might want to wait and see how that pans out, just in case ZLCS falls further from here, and then readjust stops. I would rather just buy this off strength once it clears both its 50-day and 200-day with heavy volume. One could simply use a stop just below 95 cents if you buy it off strength.

To see more hot under-$10 equities, check out the Stocks Under-$10 Setting Up To Explode portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.


Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to and maintains the website, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.
6 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,877.65 +72.85 0.41%
S&P 500 2,072.05 +1.40 0.07%
NASDAQ 4,774.43 +9.05 0.19%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs